Medivir enrols first patient in combination trial for refractory solid tumours

Swedish pharmaceutical company Medivir has started patient enrolment in a Phase I/II clinical trial of its product candidate birinapant in combination with Merck ’s anti-PD-1 therapy Keytruda (pembrolizumab) for treatment-refractory solid tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news